PharmaFocus Today – Page 15 – media

Jianyou Holdings’ subsidiary obtains FDA approval for relocation of daunorubicin hydrochloride injection production site

On June 9, Jianyou shares(603707) announced that its subsidiary Meitheal Pharmaceuticals, Inc. recently obtained the approval letter for the transfer of the production site of daunorubicin hydrochloride injection (20mg/4mL, ANDA No.: 065035) issued by the U.S. FDA, approving the production at Jianjin Pharmaceutical Co., Ltd. The drug is suitable for the treatment of adult acute non-lymphocytic leukemia and can be used in combination with other anticancer drugs. The announcement mentioned that the company has invested about 830,000 yuan in research and development costs in the project of relocating the production site of daunorubicin hydrochloride injection. The newly approved product will be marketed in the United States and is expected to have a positive impact on the company’s operating performance. In the first quarter of 2025, Jianyou Shares achieved revenue of 885 million yuan and net profit attributable to shareholders of the parent company of 84.71 million yuan. https://finance.eastmoney.com/a/202506093425522822.html
- Source: drugdu
- 47
- June 11, 2025
Erkang Pharmaceutical’s Vitamin B6 Injection Passed Consistency Evaluation

On June 9, Erkang Pharmaceutical(300267) released an announcement, vitaminThe B6 injection 1ml:100mg specification has passed the generic drug quality and efficacy consistency evaluation. The company recently received the “Notice of Approval of Supplementary Drug Application” approved by the State Drug Administration, with the approval number of National Medicine Standard H20258096. The drug is mainly used for the prevention and treatment of vitamin B6 deficiency and is included in the “National Basic Medical Insurance”, Work-related Injury Insurance and Maternity Insurance Drug List (2024)”, which is a Class A medical insurance drug. In the first quarter of 2025, Erkang Pharmaceutical achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 28.11 million yuan. https://finance.eastmoney.com/a/202506093425512121.html
- Source: drugdu
- 51
- June 11, 2025
Huaren Pharmaceutical’s wholly-owned subsidiary obtains registration certificate for phenylephrine hydrochloride injection

On June 9, Huaren Pharmaceutical announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical has obtained the Drug Registration Certificate for Phenylephrine Hydrochloride Injection approved and issued by the State Drug Administration. The drug is a prescription drug with a specification of 5ml: 0.5mg. It is registered as a Class 3 chemical drug. The drug approval number is National Medicine Standard H20254431, which is valid until June 2, 2030. Phenylephrine hydrochloride injection is mainly used to treat clinical hypotension caused by vasodilation during anesthesia and is listed as a Class B product of the national medical insurance. According to statistics from Yaozhi.com, the sales of this drug in domestic hospitals in 2024 will be 119 million yuan. In the first quarter of 2025, Huaren Pharmaceutical achieved revenue of 303 million yuan and net profit attributable to shareholders of the parent company of 16.03 million yuan. https://finance.eastmoney.com/a/202506093425445718.html
- Source: drugdu
- 46
- June 11, 2025
Drugdu.com to Exhibit at CPhI China 2025, Marking Nine Years of Advancing Global Connectivity in the Pharmaceutical Sector

The 22nd edition of CPhI China will be held from June 24 to 26, 2025, at the Shanghai New International Expo Centre. Drugdu.com, a global B2B platform specializing in pharmaceutical and medical product trade, will exhibit at Booth W4E80, presenting its latest capabilities in driving digital connectivity across the international healthcare market. Nine Years of Global Trade Enablement and Digital Efficiency Since its founding in 2016, Drugdu.com has evolved into a trusted digital infrastructure serving the global pharmaceutical supply chain. The platform currently connects verified buyers and suppliers across 220+ countries and regions, covering key sectors such as active pharmaceutical ingredients (APIs), finished dosage forms, intermediates, medical devices, diagnostics (IVD), and health products etc. With its data-driven approach, Drugdu.com enhances the efficiency of global sourcing and distribution by enabling precise lead distribution, behavioral analytics, and region-specific market insights. Rather than replicating traditional marketplace models, it focuses on helping users make ...
- Source: drugdu
- 101
- June 11, 2025
Pegcetacoplan Maintains Kidney Benefits at 52 Weeks

Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to 52-week results from the VALIANT trial. The 26-week results, which were presented last October at Kidney Week 2024, showed a highly significant difference in change in proteinuria from baseline, as measured by the urine protein-to-creatinine ratio (uPCR); the reduction was 67.2% with pegcetacoplan vs 2.9% with placebo (P < .0001). The current findings showed that not only were these benefits sustained in patients who remained on pegcetacoplan, patients who switched from placebo to pegcetacoplan also experienced reductions of similar magnitude, said Fadi Fakhouri, MD, of Lausanne University Hospital and the University of Lausanne, Switzerland. Fakhouri presented the 1-year results at the 62nd European Renal Association (ERA) Congress 2025. VALIANT Open-Label Period The phase 3 VALIANT trial involved 124 patients with ...
- Source: drugdu
- 165
- June 10, 2025
Virtual Nursing Saves Hospitals Money on Turnover Costs, Ardent Health CMO Says

Ardent Health is deploying virtual nurse technology to ease workflow burdens on bedside nurses by offloading routine tasks — and its nurse turnover rate has dropped from 15.5% to 9.5%. The health system is also using virtual specialty consults to enhance care in rural hospitals, cutting unnecessary transfers by 85% and enabling more patients to receive quality care close to home. In this day and age, hospitals can no longer afford to overlook workflow improvement, according to FJ Campbell, chief medical officer at Ardent Health(Opens in a new window). He pointed this out during an interview last month at the Reuters Digital Health conference(Opens in a new window) in Nashville, noting that the pandemic highlighted just how overwhelming hospital workflows can be. The fragmented, cumbersome nature of these workflows led to high levels of staff burnout and turnover, as well as unsustainable reliance on contract labor, Campbell explained. “We needed ...
- Source: drugdu
- 70
- June 10, 2025
Yuandong Biotechnology won the China Patent Excellence Award

On June 8, Yuandong Bio(688513) announced that the company recently won the 25th China Patent Excellence Award in recognition of its invention patent for bisoprolol fumarate tablets (Sulele®) “a bisoprolol fumarate I crystal form and its preparation method”. This award was sponsored by the State Intellectual Property OfficeThe Bureau and the World Intellectual Property Organization jointly organized the company’s innovative drugIt is a high recognition of the efforts made in biological research and development and intellectual property protection. This award is not expected to have a significant impact on the company’s current operating performance, but it demonstrates the drug’s significant advantages in terms of technological advancement, innovation and clinical value. In the future, the company will continue to strengthen its patent layout and strive to develop more high-quality innovative drugs . In the first quarter of 2025, Yuandong Bio achieved revenue of 306 million yuan and net profit attributable to ...
- Source: drugdu
- 93
- June 10, 2025
Signed a strategic cooperation agreement with Novazon

Nuotai Biotechnology, on the evening of June 6, the company announced that it had entered into an agreement with Nanjing Novozymes Biotech Co., Ltd. (hereinafter referred to as ” Novozyme “) recently signed the ” Synthetic Biology” in Nanjing Based on the synthetic biology technology platform and combining cross-cutting technologies such as organic synthesis and chemical processes, the two parties will jointly promote technological progress and project cooperation in the field of synthetic biology . The company plans to jointly establish a biopharmaceutical company with Novagen , with the company holding 51% and Novagen holding 49%. After the establishment of the joint venture, it will be included in the company’s consolidated financial statements, and will serve as a platform for subsequent cooperation and specific business. The specific investment scale, construction plan and other matters of the cooperation project will be separately agreed upon by both parties and the internal review ...
- Source: drugdu
- 61
- June 10, 2025
Dashenlin established a comprehensive outpatient company, including medical beauty service business

Guangxi Dashenlin Shenliu Comprehensive Clinic Co., Ltd. was established, with Pan Guolu as the legal representative, and a registered capital of RMB 1 million. Its business scope includes: medical services; Drug retail; Class III medical devices business operation; Food Internet sales; Medical device Internet information services; traditional Chinese medicine decoction service; medical beauty services, etc. Qichacha’s equity penetration shows that the company is indirectly wholly owned by Dasanlin . https://finance.eastmoney.com/a/202506093425405622.html
- Source: drugdu
- 65
- June 10, 2025
Johnson & Johnson announces the launch of Tenoyada in China, bringing a new standard of treatment to patients with inflammatory bowel disease

Johnson & Johnson, it was announced today that Tenoyada (gusekizumab injection (intravenous infusion)) has been launched in China for the treatment of adult patients with moderately to severely active Crohn’s disease and ulcerative colitis who have had an inadequate response, loss of response, or intolerance to traditional treatments or biologics. Tenoyada (gusekizumab injection (intravenous infusion)) was approved in February this year for the induction treatment of moderately to severely active Crohn’s disease and in April for the induction treatment of ulcerative colitis. Tenoyada (gusekizumab injection) was approved in 2019 for the treatment of psoriasis, and in February this year, it was expanded to maintenance treatment of moderately to severely active Crohn’s disease, and in April, it was expanded to maintenance treatment of ulcerative colitis. Over the past few decades, the incidence of Crohn’s disease and ulcerative colitis in China has continued to rise, and the peak age of onset has ...
- Source: drugdu
- 62
- June 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.